Guangzhou Wondfo Biotech Co., Ltd. (300482) stated on November 19 in response to investor inquiries that the company currently has no testing products related to rhinovirus. In anticipation of a potential influenza peak, Wondfo Biotech has introduced an integrated respiratory pathogen testing solution combining reagents, instruments, and information systems based on the characteristics of the current flu season. This solution aims to reduce patient waiting times and assist medical institutions in smoothly managing the surge in flu testing demand.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments